Clinical trials: Pancreatic Adenocarcinoma Locally Advanced
Pancreatic Cancer
Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00878657
- Testing
- gemcitabine hydrochloride, intensity-modulated radiation therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Rutgers, The State University of New Jersey
Pancreatic Cancer
Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00376948
- Testing
- genistein, erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Gastric Cancer, Gastroesophageal-junction Cancer
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
This is a Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal…
- Conditions
- Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer
- Trial name
- NCT05539430
- Testing
- LB1908
- Where
- 9 sites in United States
- Volunteers
- 56 people
- Sponsor
- Legend Biotech USA Inc
Pancreatic Ductal Adenocarcinoma
NALIRIFOX as Induction Therapy in LAPC
This is a prospective, single arm, single center, phase II study of NALIRIFOX as conversion therapy in patients with locally advanced pancreatic cancer.
- Trial name
- NCT06467565
- Testing
- Liposomal irinotecan
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Acinar Cell Carcinoma
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of vaccine therapy when given together with sargramostim in treating patients with locally advanced or metastatic pancreatic cancer that cannot be removed by surgery.
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT00669734
- Testing
- Falimarev, Inalimarev, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Adenocarcinoma of the Pancreas
Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas
The durg vorinostat (Zolinza) is a type of drug called an histone deacetylase (HDAC) inhibitor. It inhibits a group of enzymes called histone deacetylases. These enzymes help cancer cells survive.
- Trial name
- NCT00948688
- Testing
- Radiation therapy, 5-FU, Vorinostat
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Pancreatic Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00026130
- Testing
- fluorouracil, gemcitabine hydrochloride, radiation therapy
- Where
- 77 sites in United States
- Volunteers
- 81 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-8 months of chemotherapy.
- Conditions
- Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- LAP100 (NCT06958328)
- Testing
- Biopsy Procedure, Biospecimen Collection, Capecitabine
- Where
- 333 sites in United States, Canada
- Volunteers
- 356 people
- Sponsor
- NRG Oncology
Pancreatic Adenocarcinoma
Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma
The purpose of this study is to determine whether the experimental vaccine "modified CEA peptide CAP 1 -6D" (mCEA) can produce an immune response in patients with pancreatic cancer who have received chemotherapy and radiation…
- Trial name
- NCT00203892
- Testing
- modified CEA peptide (10mcg), modified CEA peptide (100mcg), modified CEA peptide (1000mcg)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Chicago
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
To find the recommended dose of NBTXR3 that can be given in combination with radiation therapy to patients with pancreatic cancer. To learn if the dose NBTXR3 found in Part 1 can help to control the disease.
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
- Trial name
- NCT04484909
- Testing
- Hafnium Oxide-containing Nanoparticles NBTXR3, Radiation Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
The purpose of the phase 2 component of this study is to determine if giving the immune molecule NPC-1C to individuals who have cancer of the pancreas or gastrointestinal tract (colon or rectum) which has not responded to…
- Trial name
- NCT01040000
- Testing
- NPC-1C/NEO-102
- Where
- 6 sites in United States
- Volunteers
- 94 people
- Sponsor
- Precision Biologics, Inc
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
This phase II trial tests how well photoradiation with verteporfin and pembrolizumab plus standard of care chemotherapy works in treating patients with pancreatic cancer that cannot be removed by surgery (unresectable), that has…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
- Trial name
- NCT06381154
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
Pancreatic Adenocarcinoma
Pilot Study of EUS-Guided Radiofrequency and FOLFIRINOX in Advanced Pancreatic Cancer (RadioFAP )
Pancreatic adenocarcinoma (PDAC) constitutes 90% of pancreatic tumors and is projected to become the second leading cause of cancer-related mortality in Europe by 2030.
- Trial name
- RadioFAP (NCT06743386)
- Testing
- Therapeutic procedure combines EUS-Guided Radiofrequency Ablation (RFA)
- Volunteers
- 30 people
- Sponsor
- French Society of Digestive Endoscopy
Pancreatic Cancer, Adenocarcinoma of the Pancreas
Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer
The main purpose of this study is to learn whether or not the combination of gemcitabine, bevacizumab and erlotinib works in treating patients with advanced or metastatic pancreatic cancer. Bevacizumab is a new anti-cancer drug.
- Trial name
- NCT00366457
- Testing
- Bevacizumab, Erlotinib, Gemcitabine
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Pancreatic Adenocarcinoma
NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer
The purpose of this study is to evaluate the safety and feasibility of the NanoKnife Low Energy Direct Current (LEDC) System when used to treat unresectable pancreatic adenocarcinoma.
- Trial name
- NCT01369420
- Testing
- NanoKnife Low Energy Direct Current (LEDC) System Ablation
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Angiodynamics, Inc.
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Locally Advanced Pancreatic Adenocarcinoma, Locally Advanced Pancreas Cancer
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
The purpose of this study is to assess the safety, tolerability and efficacy of XER-001 and identify a best dose for future studies.
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Locally Advanced Pancreas Cancer, Locally Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- XER-001 (NCT07157033)
- Testing
- XER-001
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Xerient Pharma
Pancreatic Ductal Adenocarcinoma
A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
The researchers are doing this study to find out whether using the chemotherapy regimen NALIRIFOX in combination with ablative dose radiation therapy (AD-XRT) and the standard chemotherapy drug capecitabine is an effective…
- Trial name
- NCT05851924
- Testing
- NALIRIFOX, AD-XRT and Capecitabine
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Neoplasm, Metastatic Pancreatic Cancer
Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer
This is an open-label, non-randomized, single-arm phase Ⅱ study aiming to evaluate the efficacy and safety profile of above-mentioned combination strategy in first-line therapy-failed advanced pancreatic cancer.
- Conditions
- Pancreatic Neoplasm, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
- Trial name
- ATNPA (NCT04718701)
- Testing
- Anlotinib+Toripalimab+Nab-paclitaxel
- Where
- China
- Volunteers
- 53 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Locally Advanced Digestive System Neuroendocrine Carcinoma, Locally Advanced Pancreatic Neuroendocrine Carcinoma
Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
This phase II trial studies how well liposomal irinotecan, leucovorin, and fluorouracil work in treating patients with high grade neuroendocrine cancer of gastrointestinal, unknown, or pancreatic origin that does not respond to…
- Conditions
- Locally Advanced Digestive System Neuroendocrine Carcinoma, Locally Advanced Pancreatic Neuroendocrine Carcinoma, Metastatic Digestive System Neuroendocrine Carcinoma, Metastatic Pancreatic Neuroendocrine Carcinoma
- Trial name
- NCT03736720
- Testing
- Fluorouracil, Leucovorin, Liposomal Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Roswell Park Cancer Institute